Skip to main content
Clinical Trials/NCT03172572
NCT03172572CompletedNot Applicable

Outcomes After Minimally Invasive or Open Pancreatoduodenectomy in High-volume Centers; a Pan-European Retrospective Propensity-score Matched Cohort Study

S (Sjors) Klompmaker, MD1 site in 1 country4,220 target enrollmentStarted: February 1, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
4,220
Locations
1
Primary Endpoint
Major morbidity

Study Overview

Brief Summary

RATIONALE: Minimally-invasive pancreatoduodenectomy (MIPD), either laparoscopic or robot-assisted, has been suggested as a valuable alternative to open pancreatoduodenectomy (OPD). The generalizability of the current literature is, however, unknown since randomized studies are lacking, and current data are published from few, very high volume centers and selection bias with a lack of case-matched series. International studies are lacking completely.

OBJECTIVE: To compare outcomes of MIPD versus open pancreatoduodenectomy (OPD), in high-volume European pancreas centers (>10 MIPDs per year, total >20 PDs per year).

METHODS: A retrospective multicenter propensity-score matched cohort study including all consecutive patients who underwent MIPD (or MI total pancreatectomy) between January 2012 and December 2016, for pancreatic head, bile duct, or duodenal cancer or cysts except chronic pancreatitis. Predefined electronic case report forms will be disseminated amongst participating centers. Participants are responsible for their own data collection. Matching of MIPD cases (collected from participating centers) to OPD controls (extracted from Dutch and German national registries) will be based on propensity scores determined by logistic regression including preoperative variables: year of surgery, demographics, BMI, ASA, comorbidities, tumor size, tumor etiology (diagnosis), and multivisceral resection. Primary outcome is 90-day major morbidity(Clavien-Dindo ≥ 3a). Secondary outcomes are 90-day postoperative events including: pancreatic fistula, length of hospital stay, R0 (microscopically negative) resection margin, malignant lymph node ratio, days to adjuvant therapy and overall survival.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Indication for open or minimally invasive pancreatoduodenectomy
  • Pancreatic head, bile duct, or duodenal cancer or cysts

Exclusion Criteria

  • Chronic pancreatitis without suspected solid tumor.

Outcomes

Primary Outcomes

Major morbidity

Time Frame: 90-days

Clavien-Dindo grade 3a-5 complications

Secondary Outcomes

  • Length of stay(90-days)
  • Radical resection rate(90-days)
  • Malignant lymph node ratio(90-days)
  • time to adjuvant therapy(90-days)
  • Pancreatic fistulae(90-days)
  • Overall survival(90-days)

Investigators

Sponsor
S (Sjors) Klompmaker, MD
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

S (Sjors) Klompmaker, MD

PhD Candidate

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Sites (1)

Loading locations...

Similar Trials

A Pan-European Study on Minimally Invasive... | Clinical Trial